China's state medical insurance administration has lowered the procurement prices of 14 cancer drugs, asking provincial-level drug procurement platforms to follow the new standard by the end of September.
中国国家医疗保障管理部门近日降低了14种抗癌药品的采购价格，并要求省级药品采购平台在9月底前遵循新标准。
The National Healthcare Security Administration said last Saturday patients are expected to be able to buy these drugs starting from September.
国家医疗保障局上周六表示，预计从九月起，患者就可以买到这些药物了。
The decision was based on a recent circular on the adjustment of medical insurance reimbursement and procurement prices of cancer drugs.
这项决定的提出是基于最近发布的关于调整医保对抗癌药的免除比例和采购价格的通告。
The administration will further its guidance to make sure the new prices are implemented, in order to allow the public to enjoy the benefits as soon as possible, a source from the administration said.
据来自该机构的的消息人士透露，为使大众尽快享受到这项利益，他们将做进一步工作，以确保新的定价可以得以实施。

Negotiations have been underway between the administration and pharmaceutical companies to add more affordable cancer drugs to the country's medical insurance reimbursement list.
管理机构和制药企业之间的协商仍在进行中，从而将更多的人们可负担起的抗癌药物加入到医疗保险补偿目录之中。
A range of drugs have been selected, with the administration confirming the producers' willingness to further negotiate. The drugs are all crucial in dealing with hematological neoplasms and solid tumors, and have great clinical value and bode huge benefits to patients, the administration said.
目前一些药品已选定，正在确认药企是否有进一步协商的意愿。管理机构表示，这些药物对治疗血液肿瘤和实体固态瘤都至关重要，具有很大的临床价值，对患者有巨大的益处。
Negotiations launched in 2017 have lowered the prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib, as well as added them to the medical insurance reimbursement list.
经过协商，15种临床有效但价格高昂的抗癌药物的价格在2017年进行了下调，如赫赛汀、利妥昔单抗和硼替佐米，并将这些加入到了医疗保险报销清单。